How does larazotide work?

Larazotide acetate, also listed as AT-1001, is an orally active peptide that this site's profile describes as a zonulin antagonist: it is meant to tighten intestinal tight junctions and limit passage of gluten fragments. Half-life is listed as short; it acts locally in the gut. Molecular weight is about 732 daltons. In 184 people with coeliac disease on a gluten challenge, 1 mg limited gluten-induced symptoms and blunted the rise in anti-tTG antibodies, but intestinal permeability (LAMA ratio) did not differ from placebo, so the barrier mechanism it was built on was not demonstrated there. Phase 2b in 342 adults found only the 0.5 mg dose met the primary symptom endpoint; higher doses did not. The pivotal Phase 3 (307 enrolled) was terminated by the sponsor with no published efficacy result. It is not approved. This FAQ does not invent a dose. Full record at /compounds/larazotide.

Educational use only. This database summarizes published research and is not medical advice. Where a dose appears it is a record of what a trial or clinic ran, or what people describe doing, with its source attached. Nothing here is a recommendation for personal use.

Part of healing and recovery peptides. BPC-157, TB-500, GHK-Cu, and the tissue repair family, including what actually has human data.